Fwd: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer.
To: mesothelioma77@gmail.com


[1]J Cancer Res Clin Oncol. 2008 Jun 17;
Ruckhäberle E, Karn T, Hanker L, Gätje R, Metzler D, Holtrich U, Kaufmann M, Rody A

PURPOSE: Multidrug resistance (MDR) has been linked to sphingolipid metabolism and preclinical data ascribe glucosylceramide synthase (GCS) a major role for MDR especially in breast cancer cells but no profound data are available on the expression of this potential therapeutic target in clinical breast cancer specimens. METHODS: We analyzed microarray data of GCS expression in a large cohort of 1,681 breast tumors. RESULTS: Expression of GCS was associated with a positive estrogen receptor (ER) status, lower histological grading, low Ki67 levels and ErbB2 negativity (P

___
Source: http://www.hubmed.org/display.cgi?uids=18560890
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc